0.2-114-

C. [1

In re application of:

Alvaro et al.

40/500 142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Cenus Art Holt

Serial IVO	10/320,143	Group Air Grac					
File Date:	January 17, 2006	Examiner:					
For:	Substituted-4-Phenyl-Piperidin-Amides As Tachykinin Antagonists And Serotonin Reuptake Inhibitors						
Director of the P.O. Box 1450 Alexandria, VA		ce					

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

iic	opies of the references are enclosed: Ref. 1-3 opies of the references were submitted in parent application	(37 CFR
	copy of the International Search Report which issued on International A is submitted herewith. All of the publications cited learch Report are listed on the statched form PTO-1449 and Applicants ware been supplied to the U.S. Patent Office by the International Bureau.	in the International understand that copies
A. [X]	The Information Disclosure Statement submitted herewith is beir months of the filling date of the above application or date of entry of an international application or before the mailing date of a first merits, whichever event occurs last. 37 CFR 1-97(b).	into the national stage
OR []	The Information Disclosure Statement submitted herewith is mailing of a first office action or after the filing of a Request Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).	
B. []	The Information Disclosure Statement transmitted herewith is being of the filling date of the above application or the date of entry into the toth in § 1.41 of an international application or after the mailing dat Action on the merits, whichever event occurred last, but before the n (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.	national stage as set e of the first Office
[]	Applicant hereby certifies that each item of information contained in this Statement was cited in a communication from a foreign patent office application not more than three months prior to the filing of this state	in a counterpart foreign

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

The Information Disclosure Statement transmitted herewith is being filed after a final action

under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which

Issued on International Publication No. in accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this information. Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.
 [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan Registration No. 38,181

GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

Date: 3 Jan 2007

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY DOCKET NO Pl4861LISW	SERIAL NO. 10/520,143				
		IATION DIS			APPLICANT Alvaro et al				
STATEMENT BY APPLICANT (Use several sheets if necessary)					FILING DATE 1/17/2006	GROUP 1625			
			U.S. P	ATE	NT DOCUMENTS				
Examiner Initials		Document Number Date			Name		Subclass	Frling Date If Appropriate	
						\pm			
	-	-	\vdash	_		1		_	
				_		+		-	
	\vdash	_							
						+		-	
			FOREIG	N PA	TENT DOCUMENTS				
		Document Number	Date		Country	Class	Subclass	Tra Yes	nslation No
	1	WO-03 088908-A		WO					
	2	WO-04 05258-A	01 -15 -2004	WO					
	3	WO-99 25685-A	05 -27 -1999	WO					
				_		+	-	-	_
	_	OTHER D	OCUMENTS (Inclu	ding.	Author, Title, Dale, Pertinent F	ages, Etc)			
				_					
	-			_					
	_								
Examiner S	Sinnsture			In	te Considered			_	
			e Caremered						
EXAMINER I	Initial if refe d: Include o	rence considered, whoopy of this form with	ether or not citation is next communication to	in con	formance with MPEP 609. Draw lin	e through cit	ation if not a	conform	ance and